Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $53.00

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) had its target price upped by investment analysts at Piper Sandler from $52.00 to $53.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a "neutral" rating on the biopharmaceutical company's stock. Piper Sandler's price target indicates a potential upside of 0.38% from the stock's current price.

Other equities analysts also recently issued research reports about the stock. JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and raised their price objective for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Wells Fargo & Company downgraded Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and lifted their target price for the company from $58.00 to $62.00 in a research report on Monday, October 7th. Cowen reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. JMP Securities increased their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a report on Friday, November 1st. Finally, HC Wainwright lifted their price target on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the company a "buy" rating in a report on Friday. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $61.44.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock traded down $0.96 during midday trading on Friday, reaching $52.80. 2,146,512 shares of the company traded hands, compared to its average volume of 1,784,019. Halozyme Therapeutics has a 12 month low of $33.15 and a 12 month high of $65.53. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The business has a 50 day moving average of $50.23 and a two-hundred day moving average of $54.00. The firm has a market capitalization of $6.72 billion, a price-to-earnings ratio of 17.48, a price-to-earnings-growth ratio of 0.44 and a beta of 1.24.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the company's stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total value of $532,600.00. Following the sale, the senior vice president now owns 173,756 shares in the company, valued at approximately $9,254,244.56. This represents a 5.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 2.70% of the company's stock.

Institutional Trading of Halozyme Therapeutics

Several institutional investors have recently modified their holdings of the stock. Skandinaviska Enskilda Banken AB publ acquired a new position in Halozyme Therapeutics during the second quarter worth $49,000. GAMMA Investing LLC raised its stake in Halozyme Therapeutics by 67.7% during the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company's stock worth $50,000 after purchasing an additional 350 shares during the period. Toth Financial Advisory Corp acquired a new position in Halozyme Therapeutics in the 3rd quarter valued at about $57,000. FSC Wealth Advisors LLC purchased a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at approximately $65,000. Finally, Park Place Capital Corp increased its holdings in shares of Halozyme Therapeutics by 828.1% during the 3rd quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company's stock worth $78,000 after buying an additional 1,209 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.